8-K - Orchestra BioMed Holdings, Inc. | StockGist

Current Report Details

Event Type

Material Agreement+3 More

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

hereto and is incorporated herein by reference. The Series A Preferred Stock was sold in reliance upon the exemption from registration provided by Section 4(a)(

Material Agreement

Source Document

1.02

. Termination of a Material Definitive Agreement. The information required by this item with respect to the Termination and ROFR Agreement and the termination o

Material Agreement

Source Document

7.01

of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act, regardless

Regulation Fd

8.01

. Other Events. On October 27, 2025, the Company announced the first patient enrollments in the Virtue SAB in the Treatment of Coronary ISR Trial (“ Virtue Tria

Other Event

$10.00B

9.01

. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 10.1 Termination and ROFR Agreement, by and between the Orchestra BioMed, Inc., Te

Exhibits Only

Source Document

Exhibits (5)

10.1

EXHIBIT 10.1

10.2

EXHIBIT 10.2

10.3

EXHIBIT 10.3

8-K

FORM 8-K

99.1

EXHIBIT 99.1